INT307766

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.02
First Reported 2010
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 1
Total Number 1
Disease Relevance 2.13
Pain Relevance 0.44

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell differentiation (CADM1) cell adhesion (CADM1) plasma membrane (CADM1)
Anatomy Link Frequency
lymphocyte 1
CADM1 (Homo sapiens)
Pain Link Frequency Relevance Heat
tolerance 1 96.20 Very High Very High Very High
rheumatoid arthritis 8 85.40 High High
psoriasis 37 85.04 High High
Arthritis 11 69.88 Quite High
Inflammation 13 63.64 Quite High
cva 1 53.08 Quite High
Adalimumab 3 37.36 Quite Low
Etanercept 5 30.84 Quite Low
cytokine 2 5.00 Very Low Very Low Very Low
aspirin 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Adhesions 1 100.00 Very High Very High Very High
Idiopathic Thrombocytopenic Purpura 1 98.88 Very High Very High Very High
Disease 16 87.16 High High
Rheumatoid Arthritis 8 85.40 High High
Psoriasis 41 85.04 High High
Thrombosis Related Under Development 22 83.20 Quite High
Inflammatory Bowel Disease 5 82.16 Quite High
Fatigue 1 70.72 Quite High
Arthritis 5 69.88 Quite High
Fever 1 69.44 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
This is specifically interesting since efalizumab, which is a humanized anti-CD11a monoclonal antibody (IgG1) that acts by blocking the interaction of lymphocyte function-associated antigen 1 with intracellular adhesion molecule 1, was described to cause an autoimmune thrombocytopenia in 0.3% of cases, based on data of the tolerance of 3,291 efaluzimab treated patients.
Negative_regulation (blocking) of adhesion molecule 1 in lymphocyte associated with idiopathic thrombocytopenic purpura, tolerance and adhesions
1) Confidence 0.02 Published 2010 Journal BMC Dermatol Section Body Doc Link PMC2860341 Disease Relevance 2.13 Pain Relevance 0.44

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox